Glenmark gets USFDA approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (US FDA) for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the generic version of Compazine Tablets, 5 mg and 10 mg, of GlaxoSmithKline. Glenmark’s Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, will be distributed in the US by Glenmark Pharmaceuticals.

According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately $26.9 million*.

Glenmark’s current portfolio consists of 182 products authorised for distribution in the US marketplace and 46 ANDAs pending approval with the US FDA.

ANDA approvalCompazine TabletsGlenmark PharmaceuticalsProchlorperazine Maleate tabletsUSFDA
Comments (0)
Add Comment